Narrow Results Clear All
- Medical Complications 1
- Medication Errors/Preventable Adverse Drug Events 3
Search results for "North America"
Washington, DC: American Society of Hematology; 2018.
The American Society of Hematology released new guidelines on prophylaxis for venous thromboembolism, which can be a patient safety problem among hospitalized patients. Key recommendations include low-molecular-weight heparin as the preferred agent when medication prophylaxis is indicated and screening of all hospitalized patients for venous thromboembolism risk and bleeding.
Journal Article > Commentary
Delivery of optimized inpatient anticoagulation therapy: consensus statement from the Anticoagulation Forum.
Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Ann Pharmacother. 2013;47:714-724.
Anticoagulant medications are considered among the highest-risk medications in common use, due to the potential for serious bleeding complications if medication errors occur. As a result, ensuring anticoagulant safety is one of the National Patient Safety Goals. This consensus statement provides guidelines for developing safer systems for the appropriate prescribing, administration, and monitoring of anticoagulant drugs in the hospital setting, as well as for minimizing adverse events after hospital discharge in patients receiving these medications. A serious medication error due to incorrect dosing of warfarin is discussed in an AHRQ WebM&M commentary.
MedWatch Safety Alert. Silver Spring, MD: US Food and Drug Administration; February 6, 2007.
This announcement alerts health care providers to the potential for life-threatening errors involving two heparin products and provides recommendations to minimize mistakes.
Journal Article > Study
Excess dosing of antiplatelet and antithrombin agents in the treatment of non–ST-segment elevation acute coronary syndromes.
Alexander KP, Chen AY, Roe MT, et al; CRUSADE Investigators. JAMA. 2005;294:3108-3116.
Treatment of acute coronary syndromes (ACS) benefits from extensive research outlining evidence-based practices for improving the quality of such care. This study discovered that more than 40% of patients presenting with ACS received at least one dose of an antithrombotic medication outside the recommended dosing range. These excess doses lead to greater risks of bleeding; the investigators estimate that 15% of patients experience major bleeding due to these prescribing errors. The findings suggest an alarmingly high rate of potential errors and adverse outcomes for ACS patients. The risks also seem directed at vulnerable populations such as elderly patients with specific comorbidities (eg, diabetes, renal insufficiency, and heart failure). With appropriate increases in utilization of antithrombotic agents for conditions such as ACS, greater attention must focus on safe initial dosing practices to prevent adverse drug events.
Journal Article > Study
Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
Budnitz DS, Pollock DA, Mendelsohn AB, Weidenbach KN, McDonald AK, Annest JL. Ann Emerg Med. 2005;45:197-206.
This project studied the epidemiologic viability of using an injury surveillance system to track outpatient adverse drug events (ADEs) treated in hospital emergency departments. The authors found that the system could play a useful role in helping to understand outpatient ADEs, identifying areas for research, and monitoring ADE prevention.